Since our earlier articles on Neridronate treatment for CRPS, it has become apparent that large numbers of CRPS sufferers have sought information on travelling to Italy to undergo the treatment. Indeed a simple online search will testify, Neridronate treatment packages are now readily available. One website even features video testimonials from a number of people who have undergone the treatment.
More detailed information on clinical criteria and (crucially) cost is a little more difficult to come by. However, we understand that providers have been more reluctant to treat those with established CRPS. As Libby Parfitt pointed out in her article:
“The Italian team freely admit that those who’ve had CRPS for longer may not experience the same results but they claim that the treatment is “still effective” even for those who’ve had CRPS for years. There are no published papers on trials involving neridronate with patients who have longstanding CRPS, but there are papers on other bisphosphonates that suggest that the treatment might benefit them. It’s just likely that the effect will not be as pronounced as the “cure” patients with younger CRPS might experience.”
In some cases people have been told that treatment will not be considered until they have undergone (and paid for) a Triphasic Bone Scan.
As to the overall cost, remember that the cost of travel and accommodation must be factored in. We understand from one source that the clinical costs alone may be in the region of £14,000. Clearly, the fall in the value of the pound has not been favourable to those in the UK looking to travel for treatment.
When seen in the context of other treatment modalities paid for privately (eg £30,000+ for a spinal cord stimulator and £10,000 – £18,000 for inpatient rehabilitation), this may be a small price to pay for what may, for some people, result in total remission from their CRPS symptoms.
In reality, however, these sums are entirely unaffordable for the majority of those with CRPS, many of whom are unable to work either full-time or at all. If a CRPS sufferer is in litigation, they should discuss with those representing them whether funding may be available as part of their claim.
We shall continue to keep you advised of any further developments in the availability of Neridronate treatment.
You may also be interested in the following articles: